Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2362552rdf:typepubmed:Citationlld:pubmed
pubmed-article:2362552lifeskim:mentionsumls-concept:C0034837lld:lifeskim
pubmed-article:2362552lifeskim:mentionsumls-concept:C0013030lld:lifeskim
pubmed-article:2362552lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:2362552lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:2362552lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:2362552lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:2362552lifeskim:mentionsumls-concept:C0641807lld:lifeskim
pubmed-article:2362552pubmed:issue26lld:pubmed
pubmed-article:2362552pubmed:dateCreated1990-8-7lld:pubmed
pubmed-article:2362552pubmed:abstractTextApparent affinities (Ki) of (E)- and (Z)-N-(iodoallyl)spiperone [E)- and (Z)-NIASP) for dopamine D2 and serotonin 5-HT2 receptors were determined in competition binding assays. (Z)-NIASP (Ki 0.35 nM, D2; Ki 1.75 nM, 5-HT2) proved slightly more potent and selective for D2 sites in vitro than (E)-NIASP (Ki 0.72 nM, D2; Ki 1.14 nM, 5-HT2). In vivo, radioiodinated (E)- and (Z)-[125I]-NIASP showed regional distributions in mouse brain which are consonant with prolonged binding to dopamine D2 receptors accompanied by a minor serotonergic component of shorter duration. Stereoselective, dose-dependent blockade of (E)-[125I]-NIASP uptake was found for drugs binding to dopamine D2 sites, while drugs selective for serotonin 5-HT2, alpha 1-adrenergic and dopamine D1 receptors did not inhibit radioligand binding 2 hr postinjection. Specific binding in striatal tissue was essentially irreversible over the time course of the study, and (E)-[125I]-NIASP gave a striatal to cerebellar tissue radioactivity concentration of 16.9 to 1 at 6 hr postinjection. Thus, (E)-[125I]-NIASP binds with high selectivity and specificity to dopamine D2 sites in vivo.lld:pubmed
pubmed-article:2362552pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:languageenglld:pubmed
pubmed-article:2362552pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:citationSubsetIMlld:pubmed
pubmed-article:2362552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2362552pubmed:statusMEDLINElld:pubmed
pubmed-article:2362552pubmed:issn0024-3205lld:pubmed
pubmed-article:2362552pubmed:authorpubmed-author:WagnerH NHNJrlld:pubmed
pubmed-article:2362552pubmed:authorpubmed-author:StathisMMlld:pubmed
pubmed-article:2362552pubmed:authorpubmed-author:LeverJ RJRlld:pubmed
pubmed-article:2362552pubmed:authorpubmed-author:MusachioJ LJLlld:pubmed
pubmed-article:2362552pubmed:authorpubmed-author:ScheffelU AUAlld:pubmed
pubmed-article:2362552pubmed:issnTypePrintlld:pubmed
pubmed-article:2362552pubmed:volume46lld:pubmed
pubmed-article:2362552pubmed:ownerNLMlld:pubmed
pubmed-article:2362552pubmed:authorsCompleteYlld:pubmed
pubmed-article:2362552pubmed:pagination1967-76lld:pubmed
pubmed-article:2362552pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:meshHeadingpubmed-meshheading:2362552-...lld:pubmed
pubmed-article:2362552pubmed:year1990lld:pubmed
pubmed-article:2362552pubmed:articleTitleIn vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors.lld:pubmed
pubmed-article:2362552pubmed:affiliationDepartment of Environmental Health Sciences, Johns Hopkins University, Baltimore, Maryland 21205.lld:pubmed
pubmed-article:2362552pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2362552pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2362552pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed